3 days ago
MediMergent Launches Pilot Program Deploying Virtual Human Advocates to Facilitate Community-Based Clinical Research
ROCKVILLE, Md.--(BUSINESS WIRE)-- MediMergent, LLC, the Real-World Evidence Company, announces the launch of its newest digital platform to enhance patient engagement and education. This AI-driven solution, utilized by pharma, providers, payers, and patients is facilitated by Virtual Human Advocates (VHA) designed to incorporate personalized facial, body, voice, and language preferences of the patient. The platform will be deployed in a pilot program to reduce the workload of study coordinators at community-based research centers. The VHA will assist in screening and recruiting patients and supporting follow-up strategies related to risk assessment, medication adherence, study compliance and retention, safety reporting, emotion detection, and monitoring study activities. The Program, launched in 10 community-based research centers across the US, will leverage point-of-care digital communication tools available in the practice's waiting and examination rooms. By using the 'wait time' in both locations, the VHA will engage the captive audience in conversations related to trials open for recruitment, roles and responsibilities of trial participants, inclusion criteria, and the overall value proposition of participating in a research trial.
Sandra Garrett, Ph.D., the CEO of MediMergent states: 'At a time when more research programs are being directed towards community-based medical practices, the number of clinical trial staff has been significantly reduced. Without additional resources, practices are turning away research opportunities. Our VHAs provide intelligent and interactive methods for monitoring and tracking outcomes while communicating and supporting patient compliance and retention. The VHAs fill a critical gap by off-loading select time-consuming activities, thereby freeing up the study personnel to focus on clinical events.'
About MediMergent: MediMergent, LLC, a Real-World Evidence Company, supports a suite of AI-driven digital applications for data collection, integration, and analytics deployed in pre- and post-approval research for drugs, biologics, and medical devices. With an emphasis on 'Voice of the Patient' data, including emotion detection, intent, attitudes, behaviors, cognition, and other biomarkers, MediMergent 's technologies can impact patients' Quality of Life, adherence, persistence, stress, anxiety, and other outcome measures. Under an extended public/private partnership with the FDA, MediMergent has commercialized three digital platforms including MediManager ™ for digital management of clinical trials, MediMentor ™ for enhanced patient engagement and education, and MediMetrics ™ a curated data base that integrates multiple sources of Real-World Data and proprietary analytics to generate Real-World Evidence.
